Is EFTRW or ORCC a better dividend investment in 2026?

EFTRW currently yields 333333.33% with a 5% 5-year dividend growth rate. ORCC yields 9.79% with 5% growth. The better choice depends on your goal: EFTRW offers higher current income.

What is the dividend yield difference between EFTRW and ORCC?

EFTRW has a forward dividend yield of 333333.33% ($2.00/share annually). ORCC yields 9.79% ($1.32/share annually). The yield gap is 333323.54 percentage points.

Home › Compare › EFTRW vs ORCC

EFTRW vs ORCC: Dividend Comparison 2026

EFTRW yields 333333.33% · ORCC yields 9.79%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EFTRW wins by $8.099219044190773e+31M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EFTRW

● Live price

333333.33%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8.099219044190773e+31M

Annual income

$80,944,421,463,343,720,000,000,000,000,000,000,000.00

Full EFTRW calculator →

ORCC

● Live price

9.79%

Share price

$13.48

Annual div

$1.32

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21.4K

Annual income

$1.04

Full ORCC calculator →

Portfolio growth — EFTRW vs ORCC

📍 EFTRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EFTRW	ORCC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EFTRW + ORCC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EFTRW pays

ORCC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTRW

Annual income on $10K today (after 15% tax)

$28,333,333.33/yr

After 10yr DRIP, annual income (after tax)

$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr

ORCC

Annual income on $10K today (after 15% tax)

$832.34/yr

After 10yr DRIP, annual income (after tax)

$0.88/yr

At 15% tax rate, EFTRW beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTRW + ORCC for your $10,000?

EFTRW: 50%ORCC: 50%

100% ORCC50/50100% EFTRW

Portfolio after 10yr

$4.0496095220953863e+31M

Annual income

$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr

Blended yield

99.94%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

EFTRW

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-13.6

Piotroski

2/9

ORCC

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$16.00

+18.7% upside vs current

Range: $16.00 — $16.00

Altman Z

0.5

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTRW buys

ORCC buys

No recent congressional trades found for EFTRW or ORCC in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEFTRWORCC

Forward yield	333333.33% ✓	9.79%
Annual dividend / share	$2.00 ✓	$1.32
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0% ✓	-50%
Portfolio after 10y	$8.099219044190773e+31M	$21.4K ✓
Annual income after 10y	$80,944,421,463,343,720,000,000,000,000,000,000,000.00 ✓	$1.04
Total dividends collected	$8.098906375781879e+31M ✓	$1.0K
Payment frequency	quarterly	quarterly
Sector	Stock	BDC
Analyst consensus	Buy	Buy

Year-by-year: EFTRW vs ORCC ($10,000, DRIP)

Year	EFTRW Portfolio	EFTRW Income/yr	ORCC Portfolio	ORCC Income/yr	Gap
1← crossover	$33,344,033	$33,333,333.33	$11,190	$489.61	+$33.33M → EFTRW
2	$103,911,171,366	$103,875,493,250.26	$12,229	$256.01	+$103911.16M → EFTRW
3	$302,644,656,190,810	$302,533,471,237,448.00	$13,216	$130.74	+$302644656.18M → EFTRW
4	$823,817,797,451,856,400	$823,493,967,669,732,100.00	$14,207	$66.02	+$823817797451.84M → EFTRW
5	$2,095,836,995,961,804,000,000	$2,094,955,510,918,530,000,000.00	$15,234	$33.17	+$2095836995961804.00M → EFTRW
6	$4,983,251,920,823,462,000,000,000	$4,981,009,375,237,783,000,000,000.00	$16,317	$16.62	+$4983251920823461888.00M → EFTRW
7	$11,073,835,968,753,321,000,000,000,000	$11,068,503,889,198,040,000,000,000,000.00	$17,468	$8.32	+$1.1073835968753322e+22M → EFTRW
8	$22,999,277,308,531,336,000,000,000,000,000	$22,987,428,304,044,770,000,000,000,000,000.00	$18,695	$4.16	+$2.2999277308531335e+25M → EFTRW
9	$44,643,905,199,991,210,000,000,000,000,000,000	$44,619,295,973,271,085,000,000,000,000,000,000.00	$20,006	$2.08	+$4.464390519999121e+28M → EFTRW
10	$80,992,190,441,907,720,000,000,000,000,000,000,000	$80,944,421,463,343,720,000,000,000,000,000,000,000.00	$21,407	$1.04	+$8.099219044190773e+31M → EFTRW

EFTRW vs ORCC: Complete Analysis 2026

EFTRW — Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Full EFTRW Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →

📬

Get this EFTRW vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTRW vs SCHD EFTRW vs JEPI EFTRW vs O EFTRW vs KO EFTRW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.